TrialReader


Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

NCT07166315 — Recruiting, 700 participants, Adelphi Real World

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor

RegistryNCT07166315
StatusRecruiting
Study typeObservational
Enrollment700 (Estimated)
SponsorAdelphi Real World (Industry)
ConditionsAxial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
Interventionsobservational study (Other)
Datesstart 2025-07-07, primary completion 2027-07-31 (estimated), completion 2027-07-31 (estimated), first posted 2025-09-10, last updated 2026-10-27
Locations1 site in United Kingdom

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Axial Spondylarthritis (axSpA) All trials for Psoriatic Arthritis (PsA) All trials of observational study

-Summary

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Expand all sections  ·  Collapse all

+Detailed description

Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.

+Arms and interventions

ArmTypeInterventionsDescription
Axial spondyloarthritis (axSpA)Other: observational studyPatients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.
Psoriatic arthritis (PsA)Other: observational studyPatients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.
  • observational study (Other): This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

+Outcome measures

Primary outcomes

  • Number of participants that have achieved Low Disease Activity (LDA) at 12 months. [At 12 months]
  • Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months. [At 12 months]
  • Change from baseline in PROM scores at 12 months. [At 12 months]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
* Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
* Participant is aged 18 years or older at enrolment.

Exclusion Criteria:

-Participation in a clinical trial at enrolment.

+Locations (1)

FacilityCityCountryStatus
Royal National Hospital for Rheumatic DiseasesBath, SomersetUnited KingdomRecruiting

My Notes